Viewing Company
Company Name:
XTL BIOPHARMACEUTICALS LTD.
CIK:
1023549
Phone:
None
Fiscal Year End:
None
Entity Type:
SIC:
-
Category Type:
Entity Name:
None
First Filing Date:
2018-03-15
Last Filing Date:
2025-04-30
SEC Filings
| Start | End | Frame | Filed | ACCN | Value | View |
|---|---|---|---|---|---|---|
| 2022-04-01 | 2022-06-30 | CY2022Q2I | 2022-08-24 | 0001213900-22-050669 | $ 194,000 | View |
| 2017-01-01 | 2017-12-31 | CY2015 | 2018-03-15 | 0001213900-18-003028 | $ 470,188,629 | View |
| 2018-01-01 | 2018-12-31 | CY2016 | 2019-03-11 | 0001213900-19-003911 | $ 514,205,799 | View |
| 2019-01-01 | 2019-12-31 | CY2017 | 2020-03-12 | 0001213900-20-006104 | $ 514,205,799 | View |
| 2021-01-01 | 2021-12-31 | CY2021Q4I | 2022-03-30 | 0001213900-22-016244 | $ 8,000,000 | View |
| 2022-01-01 | 2022-12-31 | CY2022 | 2023-03-22 | 0001213900-23-021869 | $ 2,000 | View |
| 2024-01-01 | 2024-08-14 | CY2024Q2I | 2025-04-30 | 0001213900-25-037590 | $ 138,000 | View |
| 2020-01-01 | 2020-12-31 | CY2018 | 2021-03-15 | 0001213900-21-015290 | $ 2,411,000 | View |
| 2020-01-01 | 2020-12-31 | CY2019Q4I | 2021-05-19 | 0001213900-21-027792 | $ 2,411,000 | View |
| 2021-04-01 | 2021-06-30 | CY2021Q2I | 2021-08-24 | 0001213900-21-044544 | $ 3,379,000 | View |
SEC Facts By Type
| Type | Name | Description | View |
|---|---|---|---|
| dei | Entity Common Stock, Shares Outstanding | Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. | View |
| ifrs-full | 3437619 | None | View |
| us-gaap | Additional Paid in Capital | Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. | View |
| us-gaap | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. | View |
| us-gaap | Marketable Securities, Current | Amount of investment in marketable security, classified as current. | View |